BioLife Solutions is a pure-play provider of biopreservation and cell processing tools for cell-based therapies, supporting critical steps in preparation, transfer, and recovery. The company completed a portfolio refocusing in 2024-2025, divesting Storage & Services (SciSafe, evo) and Freezers (CBS, Stirling) to concentrate on core cell processing tools and biopreservation media. FY 2025 revenue was $96 million, with 29% organic revenue growth (pro forma for evo divestiture). FY 2025 Adjusted EBITDA Margin was 26% and Gross Margin was 65% (pro forma for evo divestiture). BioLife products are specified in over 950 active global cell-based therapy trials and approximately 250 active US commercially-sponsored trials. CryoStor, their cryopreservation media, is specified in over 80% of active Phase 3 US commercially-sponsored cell-based therapy trials. The company expects 17-20% revenue growth for FY 2026 and anticipates positive GAAP net income for the full year. Planned capital projects include a $5.5 million media capacity expansion in Bothell, WA (Q1 2026 expected completion) and a ~$15 million de novo facility in Indianapolis, IN (H2 2027 expected completion).